Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kolon/Mitsubishi Gene Therapy Pact Paves Way For More Global Deals?

Executive Summary

In a rare large gene therapy deal, South Korea’s Kolon is making inroads into the Japanese market through Invossa, its genetically modified allogeneic cell therapy for osteoarthritis. The agreement with Mitsubishi Tanabe could pave the way for more global licensing agreements in a growing segment.


Related Content

Spotlight On TissueGene’s Upcoming Korea IPO
First Approval For Kolon's Invossa But No Disease-Modifying Status
Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
New OA Cell Therapy On Horizon As JointStem Study Succeeds
2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
Deal Watch: Bristol Leaves Neuropathic Pain Candidate To Lexicon
How Are Japan’s Regenerative Meds Regs Playing Out?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts